Considering the complex beneficial effect of SGLT2 inhibitors and GLP1-R agonists on both GV and CV outcomes further supports that this pharmacological strategy is more appropriate for the T2DM patient treatment. Here, SLC5A2 is linked to type 2 diabetes mellitus.